Litigation Summary and Analysis for ALKERMES, INC. v. TEVA PHARMACEUTICALS, INC. | 1:25-cv-14685
Introduction
This litigation concerns patent infringement allegations filed by Alkermes, Inc. against Teva Pharmaceuticals, Inc., regarding proprietary pharmaceutical compositions and methods related to Alkermes’ patented drug delivery technologies. The case, docket number 1:25-cv-14685, demonstrates the complex interplay between patent rights, generic drug market entry, and innovation in the pharmaceutical industry.
Case Background
Alkermes, Inc., a biopharmaceutical company specializing in drug delivery technologies, filed suit against Teva, alleging that Teva infringed intellectual property rights associated with Alkermes’ proprietary formulations and delivery mechanisms. The core patents involve advanced sustained-release formulations that Alkermes developed for treatment modalities, including opioid use disorder and psychiatric disorders.
Teva, a major generic pharmaceutical manufacturer, intended to develop and market a generic equivalent, prompting Alkermes to seek judicial intervention to prevent infringement and safeguard its patent rights.
Legal Claims and Patent Allegations
Alkermes asserted multiple patent claims, primarily U.S. Patent No. 9,851,759 and related patents, covering specific sustained-release drug compositions and delivery…
